NCT06100796View on ClinicalTrials.gov

Effect of DM on Outcomes and Response Rate in Patients With Advanced NSCLC on ICI

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions
Non Small Cell Lung Cancer MetastaticDiabetes Mellitus
Interventions
COMBINATION_PRODUCT

Pembrolizumab

Immune check inhibitor with OHA

Trial Locations (1)

71515

RECRUITING

Assiut university, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT06100796 - Effect of DM on Outcomes and Response Rate in Patients With Advanced NSCLC on ICI | Biotech Hunter | Biotech Hunter